Teva drops 3% as market re-prices weaker 2026 sales outlook
Teva shares fell about 3% on April 24, 2026, as investors refocused on the company’s weaker 2026 revenue outlook after a recent run-up. The company has guided to 2026 sales of $16.4–$16.8 billion and adjusted EPS of $2.57–$2.77, with the revenue range viewed as light versus prior expectations.
1) What’s moving TEVA today
Teva Pharmaceutical Industries’ U.S.-listed ADS (TEVA) traded lower on Friday, April 24, 2026, down about 3% to around $30.30. The move looks driven by investors revisiting the company’s 2026 outlook and the growth cadence implied by guidance, rather than a single new headline.
2) The fundamental overhang: 2026 outlook
Teva’s most recent full-year view has pointed to 2026 revenue of $16.4–$16.8 billion and adjusted EPS of $2.57–$2.77. Earlier price action in the name has been sensitive to how quickly the innovative portfolio can offset normalization in certain generic contributions, so any “growth slows” narrative can trigger profit-taking even absent incremental company news. (bloomberg.com)
3) What to watch next
Traders will be looking for near-term catalysts that can shift sentiment back to product-driven upside: updates on launches and trajectories for key brands (including the migraine franchise) and any additional detail on 2026 demand assumptions embedded in guidance. Absent fresh catalysts, the stock may continue to trade as a push-pull between innovative brand momentum and the market’s skepticism about the top-line path implied by the 2026 range. (fiercepharma.com)